<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03883113</url>
  </required_header>
  <id_info>
    <org_study_id>FLU010</org_study_id>
    <nct_id>NCT03883113</nct_id>
  </id_info>
  <brief_title>Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model</brief_title>
  <official_title>Efficacy of MVA-NP+M1 in the Influenza H3N2 Human Challenge Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaccitech (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaccitech (UK) Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, single center, randomized, double blind study evaluating the safety, efficacy, and&#xD;
      immunogenicity of MVA NP+M1 in the H3N2 human influenza challenge model; on healthy adult&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of an outpatient vaccination phase (155 participants), and at least 2&#xD;
      months later an inpatient challenge phase (134 participants). Participants are randomized&#xD;
      93:62 to receive either MVA-NP+M1 or Placebo. Up to 20 participants will be challenged over&#xD;
      several 3-week blocks, and the remainder at the final 3-week block for a total of 80&#xD;
      MVA-NP+M1 and 54 Placebo recipients challenged.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Actual">April 17, 2020</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR</measure>
    <time_frame>Throughout 9 days (Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10) after viral Inoculation (Day1) of the challenge phase. Nasal swabs taken twice a day (b.i.d) at least 8 hours apart.</time_frame>
    <description>Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Virologically Confirmed Influenza-Like Illness</measure>
    <time_frame>9 days from day 2 to day 10</time_frame>
    <description>Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Attack Rate of Challenge Agent (qRT-PCR)</measure>
    <time_frame>9 days from day 2 to day 10</time_frame>
    <description>The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture)</measure>
    <time_frame>9 days from day 2 to day 10</time_frame>
    <description>The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Start of Viral Shedding (qPCR) From Virus Inoculation</measure>
    <time_frame>9 days from day 2 to day 10</time_frame>
    <description>The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60*60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Start of Viral Shedding (qCulture) From Virus Inoculation</measure>
    <time_frame>9 days from day 2 to day 10</time_frame>
    <description>Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60*60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Viral Shedding (qPCR) After the Virus Inoculation</measure>
    <time_frame>9 days from Day 2 to Day 10</time_frame>
    <description>This is measured by the highest viral load concentration by qPCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Viral Shedding (qCulture) After Virus Inoculation</measure>
    <time_frame>9 days from day 2 to day 10</time_frame>
    <description>This is measured by the highest viral load concentration by qCulture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation</measure>
    <time_frame>9 days from day 2 to day 10</time_frame>
    <description>This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60*60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation</measure>
    <time_frame>9 days from day 2 to day 10</time_frame>
    <description>This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60*60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Viral Shedding (qPCR) After the Virus Inoculation</measure>
    <time_frame>9 days from day2 to day10</time_frame>
    <description>It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60*60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Viral Shedding (qCulture) After the Virus Inoculation</measure>
    <time_frame>9 days from day 2 to day 10</time_frame>
    <description>It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60*60)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)</measure>
    <time_frame>11 days from Day 1 to Day 11</time_frame>
    <description>Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score.&#xD;
Symptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC).&#xD;
SSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM).&#xD;
Participants rated the severity of symptoms, higher scores indicating a more severe symptom.&#xD;
The scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work &quot;today&quot; (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3.&#xD;
The SSC AUC [0-11 days] was derived based on the Overall SSC score against time (*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score*hour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Days of Fever</measure>
    <time_frame>11 days from Day 1 to Day 11</time_frame>
    <description>Total days of fever for MVA-NP+M1 vs. Placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Total Mucus Production</measure>
    <time_frame>11 days from Day 1 to Day 11</time_frame>
    <description>Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo.&#xD;
Total mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence</measure>
    <time_frame>3 months (day 0, day 8 and day 28 of the vaccination period and day -1 and day 28 of the challenge period)</time_frame>
    <description>T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay.&#xD;
For each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO).&#xD;
The number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported.&#xD;
The endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms</measure>
    <time_frame>7 days following vaccination</time_frame>
    <description>Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms</measure>
    <time_frame>17 days following vaccination</time_frame>
    <description>Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Severity of Individual Symptoms for MVA-NP+M1 vs. Placebo</measure>
    <time_frame>11 days</time_frame>
    <description>Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Symptom Score Time to Start, Time to Peak and Duration</measure>
    <time_frame>11 days</time_frame>
    <description>Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate&#xD;
Influenza Symptom Score Card of FLU010 - Solicited symptoms for generalized, and upper and lower respiratory tract symptoms scored by severity (0: absent, 1: mild, 2: moderate, or 3: severe).</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of T Cell Phenotypes With Illness Outcomes</measure>
    <time_frame>3 months</time_frame>
    <description>Correlation of antigen specific T Cell phenotypes with illness outcomes</description>
  </other_outcome>
  <other_outcome>
    <measure>Vaccination Effect on Antibody Responses by ELISpot and ICS Assays</measure>
    <time_frame>3 months</time_frame>
    <description>Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and Intracellular Cytokine Staining (ICS)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>MVA-NP+M1 &amp; H3N2 Challenge Virus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Placebo &amp; H3N2 Challenge Virus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-NP+M1</intervention_name>
    <description>Trial Vaccine</description>
    <arm_group_label>MVA-NP+M1 &amp; H3N2 Challenge Virus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Sodium Chloride Placebo</description>
    <arm_group_label>Saline Placebo &amp; H3N2 Challenge Virus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>H3N2 (A/Belgium/2417/2015)</intervention_name>
    <description>Challenge Agent</description>
    <arm_group_label>MVA-NP+M1 &amp; H3N2 Challenge Virus</arm_group_label>
    <arm_group_label>Saline Placebo &amp; H3N2 Challenge Virus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males and females aged ≥18 and ≤55 years of age at the point of enrolment.&#xD;
&#xD;
          -  Non-smokers or those who stopped smoking ≥ 3 months prior to screening 1 visit.&#xD;
&#xD;
          -  Willingness to remain in isolation for the duration of the study.&#xD;
&#xD;
          -  A female participant is eligible for this study if she is not pregnant or breast&#xD;
             feeding and 1 of the following:&#xD;
&#xD;
               1. Of non-childbearing potential (i.e., women who have had a hysterectomy or tubal&#xD;
                  ligation or are postmenopausal, as defined by no menses in greater than or equal&#xD;
                  to 1 year).&#xD;
&#xD;
               2. Of childbearing potential but has been and agrees to continue practicing highly&#xD;
                  effective contraception or abstinence (if this is the preferred and usual&#xD;
                  lifestyle of the participant) from 6 months prior to vaccination to 6 months&#xD;
                  after administration of the influenza challenge virus. Highly effective methods&#xD;
                  of contraception include 1 or more of the following:&#xD;
&#xD;
             i. male partner who is sterile (vasectomised) prior to the female participants entry&#xD;
             into the study and is the sole sexual partner for the female participant; ii. hormonal&#xD;
             (oral, intravaginal, transdermal, implantable or injectable); iii. an intrauterine&#xD;
             hormone-releasing system (IUS); iv. an intrauterine device (IUD) with a documented&#xD;
             failure rate of &lt; 1%; v. bilateral tubal occlusion.&#xD;
&#xD;
          -  Pre-challenge serum microneutralization test (MNT) against A/Belgium/4217/2015 (H3N2)&#xD;
             challenge strain &lt; 20.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI &lt; 19 and &gt; 32.&#xD;
&#xD;
          -  Presence of any significant acute or chronic, uncontrolled medical (or psychiatric)&#xD;
             illness including a history of chronic respiratory illness.&#xD;
&#xD;
          -  History of seasonal hay fever or a clinically significant seasonal allergic rhinitis&#xD;
             (SAR), including the use of symptomatic prescription only medication and&#xD;
             non-prescription medication.&#xD;
&#xD;
          -  History or evidence of autoimmune disease or known immunodeficiency of any cause -&#xD;
             with the exception of atopic dermatitis/eczema and atopic rhinitis.&#xD;
&#xD;
          -  Any history of anaphylaxis in reaction to vaccination or history of allergic reactions&#xD;
             likely to be exacerbated by any component of the vaccine.&#xD;
&#xD;
          -  History of lung disease (Asthma, COPD).&#xD;
&#xD;
          -  Current smokers or those who stopped smoking &lt; 3months prior to screening 1 visit.&#xD;
&#xD;
          -  Positive diagnostic tests for HIV, Hepatitis B or Hepatitis C indicating active&#xD;
             infection.&#xD;
&#xD;
          -  Evidence of drug abuse or a positive urine drug screen or alcohol breath test.&#xD;
&#xD;
          -  Chronic use of any medication or other product (prescription or over-the-counter), for&#xD;
             symptoms of rhinitis or nasal congestion or for any chronic nasopharyngeal complaint,&#xD;
             or chronic use of any intranasal medication for any indication that has not ceased&#xD;
             within 30 days prior to screening 1.&#xD;
&#xD;
          -  Receipt of any investigational drug within 3 months prior to vaccination, or prior&#xD;
             participation in a clinical trial of any influenza vaccine, or any investigational&#xD;
             vaccine or experimental influenza viral challenge delivered directly to the&#xD;
             respiratory tract within 1 year prior to challenge.&#xD;
&#xD;
          -  Receipt of the 2018/2019 seasonal flu vaccine.&#xD;
&#xD;
          -  Receipt of any live vaccines within the 4 weeks prior to vaccination.&#xD;
&#xD;
          -  Any laboratory test which is abnormal and which is deemed by the Investigator(s) to be&#xD;
             clinically significant.&#xD;
&#xD;
          -  Receipt of any systemic chemotherapy agent at any time.&#xD;
&#xD;
          -  Physician reported influenza or a syndrome consistent with influenza (as judged by the&#xD;
             investigator) in the previous 6 months.&#xD;
&#xD;
          -  Known allergy to treatments for influenza (including but not limited to oseltamivir).&#xD;
&#xD;
          -  History of frequent epistaxis (nose bleeds).&#xD;
&#xD;
          -  Any nasal or sinus surgery within 6 months of Viral Challenge or any significant&#xD;
             abnormality, either of which results in alteration of the anatomy of the nose or&#xD;
             nasopharynx (including significant nasal polyps).&#xD;
&#xD;
          -  Volunteers with household contacts who are at risk for serious or severe complications&#xD;
             of influenza disease including, but not limited to: persons ≥ 65 years; presence of&#xD;
             significant chronic cardiopulmonary, metabolic, renal, or neurological conditions;&#xD;
             immunosuppression due to any condition or therapies; BMI &gt;40.&#xD;
&#xD;
          -  Participants that are an employee or family member of the Investigator or study site&#xD;
             personnel may not be enrolled.&#xD;
&#xD;
          -  Any other finding that, in the opinion of the Investigator, deems the participant&#xD;
             unsuitable for the study.&#xD;
&#xD;
        EXCLUSION (CHALLENGE PERIOD ONLY)&#xD;
&#xD;
          -  Abnormal spirometry assessed to be clinically significant.&#xD;
&#xD;
          -  Known close contact with anyone known to have influenza in the past 7 days at the time&#xD;
             of quarantine.&#xD;
&#xD;
          -  Influenza-like illness (ILI) symptoms as assessed at the admission to clinic on Day -2&#xD;
             prior to challenge.&#xD;
&#xD;
          -  Presence of fever, defined as participant presenting with a temperature reading of &gt;&#xD;
             38.0°C on admission to quarantine.&#xD;
&#xD;
          -  Qualitative Polymerase chain reaction (PCR) results positive for viral infection.&#xD;
             However, participants may be included into later challenge cohort.&#xD;
&#xD;
          -  Acute use of any medication or other product, prescription or over-the-counter, for&#xD;
             symptoms of rhinitis or nasal congestion within 7 days prior to challenge. This&#xD;
             includes any oral corticosteroid or beta agonist containing nasal spray.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Rogiers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Life Sciences, Clinical Pharmacology Unit (CPU)</name>
      <address>
        <city>Antwerp</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <results_first_submitted>December 4, 2020</results_first_submitted>
  <results_first_submitted_qc>March 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2021</results_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 10, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03883113/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03883113/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at the SGS Clinical Pharmacology Unit in Antwerp, Belgium.</recruitment_details>
      <pre_assignment_details>Eight-hundred and nineteen (819) subjects were screened. One hundred and forty-five (145) subjects were actually enrolled and vaccinated. The study consisted of an outpatient vaccination phase and at least 6 weeks later an inpatient challenge phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MVA-NP+M1 &amp; H3N2 Challenge Virus</title>
          <description>Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)&#xD;
MVA-NP+M1: Trial Vaccine&#xD;
H3N2 (A/Belgium/2417/2015): Challenge Agent</description>
        </group>
        <group group_id="P2">
          <title>Saline Placebo &amp; H3N2 Challenge Virus</title>
          <description>Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)&#xD;
Saline: Sodium Chloride Placebo&#xD;
H3N2 (A/Belgium/2417/2015): Challenge Agent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Challenge Criteria Not Met / Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MVA-NP+M1 &amp; H3N2 Challenge Virus</title>
          <description>Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)&#xD;
MVA-NP+M1: Trial Vaccine&#xD;
H3N2 (A/Belgium/2417/2015): Challenge Agent</description>
        </group>
        <group group_id="B2">
          <title>Saline Placebo &amp; H3N2 Challenge Virus</title>
          <description>Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)&#xD;
Saline: Sodium Chloride Placebo&#xD;
H3N2 (A/Belgium/2417/2015): Challenge Agent</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="145"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.00" lower_limit="18.5" upper_limit="55.9"/>
                    <measurement group_id="B2" value="41.25" lower_limit="19.9" upper_limit="55.7"/>
                    <measurement group_id="B3" value="42.50" lower_limit="18.5" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle Eastern</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Ex-smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.40" lower_limit="153.2" upper_limit="193.3"/>
                    <measurement group_id="B2" value="172.30" lower_limit="151.8" upper_limit="191.7"/>
                    <measurement group_id="B3" value="172.40" lower_limit="151.8" upper_limit="193.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.9" lower_limit="53.2" upper_limit="118.8"/>
                    <measurement group_id="B2" value="75.15" lower_limit="54.6" upper_limit="105.6"/>
                    <measurement group_id="B3" value="73.60" lower_limit="53.2" upper_limit="118.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.7" lower_limit="19.0" upper_limit="32"/>
                    <measurement group_id="B2" value="25.5" lower_limit="19.2" upper_limit="31.2"/>
                    <measurement group_id="B3" value="24.90" lower_limit="19.0" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR</title>
        <description>Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule.</description>
        <time_frame>Throughout 9 days (Day2, Day3, Day4, Day5, Day6, Day7, Day8, Day9, Day10) after viral Inoculation (Day1) of the challenge phase. Nasal swabs taken twice a day (b.i.d) at least 8 hours apart.</time_frame>
        <population>End point values</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat (the actually challenged with the virus)</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat (the actually challenged with the virus)</description>
          </group>
          <group group_id="O3">
            <title>MVA-NP+M1 (PP)</title>
            <description>Per protocol analysis set</description>
          </group>
          <group group_id="O4">
            <title>Placebo (PP)</title>
            <description>Per protocol analysis set</description>
          </group>
          <group group_id="O5">
            <title>MVA-NP+M1 (Challenge)</title>
            <description>Safety Analysis Set (challenged participants)</description>
          </group>
          <group group_id="O6">
            <title>Placebo (Challenge)</title>
            <description>Safety Analysis Set (challenged participants)</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Nasopharyngeal Viral Shedding as Determined by Quantitative Polymerase Chain Reaction qPCR</title>
          <description>Measure of nasopharyngeal viral shedding during challenge; recorded as viral area under curve (vAUC) as determined by quantitative real time polymerase chain reaction (qRT-PCR). vAUC is calculated by plotting the log viral particles number/ml for each time point against time and is using the trapezoidal rule.</description>
          <population>End point values</population>
          <units>hour*Log10 Viral Particles/ ml</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="71"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="649.7" lower_limit="552.7" upper_limit="746.7"/>
                    <measurement group_id="O2" value="726.1" lower_limit="604.0" upper_limit="848.2"/>
                    <measurement group_id="O3" value="646.5" lower_limit="548.3" upper_limit="744.7"/>
                    <measurement group_id="O4" value="726.1" lower_limit="604.0" upper_limit="848.2"/>
                    <measurement group_id="O5" value="649.7" lower_limit="552.7" upper_limit="746.7"/>
                    <measurement group_id="O6" value="726.1" lower_limit="604.0" upper_limit="848.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1711</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1654</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1711</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Virologically Confirmed Influenza-Like Illness</title>
        <description>Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result.</description>
        <time_frame>9 days from day 2 to day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Virologically Confirmed Influenza-Like Illness</title>
          <description>Incidence (frequency tabulation) of laboratory-confirmed influenza-like illness compared between vaccine and placebo arms Virologically confirmed influenza-like illness (ILI) is defined as having respiratory or flu-like symptom occurring on two consecutive days, along with a positive qPCR or qCulture result.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Virologically confirmed Influenza-like Illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Virologically Confirmed Influenza-like Illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis applies to participants with Virologically confirmed Influenza-like Illness versus participants without Virologically confirmed Influenza-like Illness</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Attack Rate of Challenge Agent (qRT-PCR)</title>
        <description>The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days</description>
        <time_frame>9 days from day 2 to day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Attack Rate of Challenge Agent (qRT-PCR)</title>
          <description>The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qRT-PCR within the timespan of two consecutive days</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>qPCR-confirmed influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.1" lower_limit="80.7" upper_limit="95.9"/>
                    <measurement group_id="O2" value="97.9" lower_limit="88.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No qPCR influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="4.1" upper_limit="19.3"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.1" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This statistical analysis applies to participants with qPCR confirmed Influenza versus participants with no qPCR confirmed Influenza</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture)</title>
        <description>The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days</description>
        <time_frame>9 days from day 2 to day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Quantitative Culture Attack Rate of Challenge Agent (qCulture)</title>
          <description>The attack rate is defined as the percentage of inoculated participants with at least two consecutive positive swabs as determined by qCulture within the timespan of two consecutive days</description>
          <units>percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>qCulture confirmed influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" lower_limit="66.0" upper_limit="86.5"/>
                    <measurement group_id="O2" value="85.1" lower_limit="71.7" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No qCulture-confirmed influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="13.5" upper_limit="34.0"/>
                    <measurement group_id="O2" value="14.9" lower_limit="6.2" upper_limit="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This statistical analysis applies to participants with qCulture confirmed Influenza versus participants without qCulture confirmed Influenza</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3504</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Start of Viral Shedding (qPCR) From Virus Inoculation</title>
        <description>The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60*60)</description>
        <time_frame>9 days from day 2 to day 10</time_frame>
        <population>[MVA-NP+M1 (ITT)] - subjects assessed = 71 subjects with event = 64 subjects censored = 7 [Placebo (ITT)] - subjects assessed = 47 subjects with event = 46 subjects censored = 1</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Start of Viral Shedding (qPCR) From Virus Inoculation</title>
          <description>The Time to Start of Viral Shedding (qPCR) is calculated as (datetime of first of two positive swabs (qPCR) within 2 consecutive days - challenge datetime)/(60*60)</description>
          <population>[MVA-NP+M1 (ITT)] - subjects assessed = 71 subjects with event = 64 subjects censored = 7 [Placebo (ITT)] - subjects assessed = 47 subjects with event = 46 subjects censored = 1</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.40" lower_limit="24.30" upper_limit="24.50"/>
                    <measurement group_id="O2" value="24.30" lower_limit="24.20" upper_limit="24.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5558</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Start of Viral Shedding (qCulture) From Virus Inoculation</title>
        <description>Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60*60)</description>
        <time_frame>9 days from day 2 to day 10</time_frame>
        <population>[MVA-NP+M1(ITT)] - Subjects assessed = 71 Subjects with event = 55 Subjects censored = 16; [Placebo (ITT)] - Subjects assessed = 47 Subjects with event = 40 Subjects censored = 7</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Start of Viral Shedding (qCulture) From Virus Inoculation</title>
          <description>Time to Start of Viral Shedding (qCulture) is calculated as (datetime of first of two positive swabs (qCulture) within 2 consecutive days - challenge datetime)/(60*60)</description>
          <population>[MVA-NP+M1(ITT)] - Subjects assessed = 71 Subjects with event = 55 Subjects censored = 16; [Placebo (ITT)] - Subjects assessed = 47 Subjects with event = 40 Subjects censored = 7</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.9" lower_limit="35.60" upper_limit="48.00"/>
                    <measurement group_id="O2" value="47.6" lower_limit="24.70" upper_limit="48.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6534</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Viral Shedding (qPCR) After the Virus Inoculation</title>
        <description>This is measured by the highest viral load concentration by qPCR</description>
        <time_frame>9 days from Day 2 to Day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT) Successful Attack</title>
            <description>Subset of participants who received MVA-NP+M1 and with a successful attack</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT) Successful Attack</title>
            <description>Subset of participants who received Placebo and with a successful attack</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Viral Shedding (qPCR) After the Virus Inoculation</title>
          <description>This is measured by the highest viral load concentration by qPCR</description>
          <units>Log10 Viral Particles/ ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.876" lower_limit="5.430" upper_limit="6.322"/>
                    <measurement group_id="O2" value="6.054" lower_limit="5.521" upper_limit="6.587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5485</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Viral Shedding (qCulture) After Virus Inoculation</title>
        <description>This is measured by the highest viral load concentration by qCulture.</description>
        <time_frame>9 days from day 2 to day 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT) Successful Attack</title>
            <description>Subset of participants who received MVA-NP+M1 and with a successful attack</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT) Successful Attack</title>
            <description>Subset of participants who received Placebo and with a successful attack</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Viral Shedding (qCulture) After Virus Inoculation</title>
          <description>This is measured by the highest viral load concentration by qCulture.</description>
          <units>Log10 Viral Particles/ ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.073" lower_limit="3.683" upper_limit="4.463"/>
                    <measurement group_id="O2" value="4.069" lower_limit="3.442" upper_limit="4.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6753</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation</title>
        <description>This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60*60)</description>
        <time_frame>9 days from day 2 to day 10</time_frame>
        <population>[MVA-NP+M1 (ITT)] - Subjects assessed = 71 Subjects with event = 64 Subjects censored = 7; [Placebo (ITT)] - Subjects assessed = 47 Subjects with event = 46 Subjects censored = 1</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak of Viral Shedding (qPCR) From the Viral Inoculation</title>
          <description>This is calculated as (datetime of highest viral load concentration (qPCR) - challenge datetime)/(60*60)</description>
          <population>[MVA-NP+M1 (ITT)] - Subjects assessed = 71 Subjects with event = 64 Subjects censored = 7; [Placebo (ITT)] - Subjects assessed = 47 Subjects with event = 46 Subjects censored = 1</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.20" lower_limit="60.00" upper_limit="96.00"/>
                    <measurement group_id="O2" value="107.90" lower_limit="72.20" upper_limit="119.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.711</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation</title>
        <description>This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60*60)</description>
        <time_frame>9 days from day 2 to day 10</time_frame>
        <population>[MVA-NP+M1 (ITT)] - Subjects assessed = 71 Subjects with event = 55 Subjects censored = 16; [Placebo (ITT)] - Subjects assessed = 47 Subjects with event = 40 Subjects censored = 7</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak of Viral Shedding (qCulture) From the Viral Inoculation</title>
          <description>This is calculated as (datetime of highest viral load concentration (qCulture) - challenge datetime)/(60*60)</description>
          <population>[MVA-NP+M1 (ITT)] - Subjects assessed = 71 Subjects with event = 55 Subjects censored = 16; [Placebo (ITT)] - Subjects assessed = 47 Subjects with event = 40 Subjects censored = 7</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.40" lower_limit="60.10" upper_limit="96.30"/>
                    <measurement group_id="O2" value="83.80" lower_limit="60.10" upper_limit="96.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4689</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Viral Shedding (qPCR) After the Virus Inoculation</title>
        <description>It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60*60)</description>
        <time_frame>9 days from day2 to day10</time_frame>
        <population>This endpoint is only calculated for the subset of participants with a successful attack.</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT) Successful Attack</title>
            <description>Subset of participants who received MVA-NP+M1 and with a successful attack</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT) Successful Attack</title>
            <description>Subset of participants who received Placebo and with a successful attack</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Viral Shedding (qPCR) After the Virus Inoculation</title>
          <description>It is calculated as (datetime of first negative swab (qPCR) following the last positive swab (qPCR) - datetime of first positive of two positive swabs (qPCR) within 2 consecutive days)/(60*60)</description>
          <population>This endpoint is only calculated for the subset of participants with a successful attack.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170.80" lower_limit="157.08" upper_limit="184.52"/>
                    <measurement group_id="O2" value="172.47" lower_limit="156.99" upper_limit="187.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Viral Shedding (qCulture) After the Virus Inoculation</title>
        <description>It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60*60)</description>
        <time_frame>9 days from day 2 to day 10</time_frame>
        <population>This endpoint is only calculated for the subset of participants with a successful attack</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT) Successful Attack</title>
            <description>Subset of participants who received MVA-NP+M1 and with a successful attack</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT) Successful Attack</title>
            <description>Subset of participants who received Placebo and with a successful attack</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Viral Shedding (qCulture) After the Virus Inoculation</title>
          <description>It is calculated as (datetime of first negative swab (qCulture) following the last positive swab (qCulture) - datetime of first positive of two positive swabs (qCulture) within 2 consecutive days)/(60*60)</description>
          <population>This endpoint is only calculated for the subset of participants with a successful attack</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.19" lower_limit="105.07" upper_limit="131.31"/>
                    <measurement group_id="O2" value="121.78" lower_limit="106.33" upper_limit="137.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)</title>
        <description>Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score.&#xD;
Symptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC).&#xD;
SSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM).&#xD;
Participants rated the severity of symptoms, higher scores indicating a more severe symptom.&#xD;
The scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work &quot;today&quot; (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3.&#xD;
The SSC AUC [0-11 days] was derived based on the Overall SSC score against time (*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score*hour.</description>
        <time_frame>11 days from Day 1 to Day 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Total Area Under the Curve (AUC) of Self-reported Influenza Total Symptom Score (SSC AUC)</title>
          <description>Total symptom scores were compared for MVA-NP+M1 vs. Placebo from Day1 to Day11 post-challenge as AUC of composite score.&#xD;
Symptoms were collected twice a day (lymphadenopathy once a day) on a Symptom Score Card(SSC).&#xD;
SSC recorded scores for each 16 general (gastrointestinal/body systemic) and 12 local (upper/lower respiratory tract) symptoms, on the scale per timepoint (for example Day2,AM).&#xD;
Participants rated the severity of symptoms, higher scores indicating a more severe symptom.&#xD;
The scores ranged from 0 to 3 (0:symptom free, 1:mild, 2:moderate, 3:severe).The SSC also contained the question whether the subject felt well to go to work &quot;today&quot; (yes/no). The Overall SSC score was calculated, as the Arithmetic Mean of the Scores collected across all 28 items on the card per Timepoint and ranged from 0 to maximum 3.&#xD;
The SSC AUC [0-11 days] was derived based on the Overall SSC score against time (*hour), using the linear trapezoidal rule and it ranged from 0 to 110 Score*hour.</description>
          <units>Composite symptom score on scale*hour</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.709" lower_limit="11.568" upper_limit="21.850"/>
                    <measurement group_id="O2" value="20.432" lower_limit="13.753" upper_limit="27.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Days of Fever</title>
        <description>Total days of fever for MVA-NP+M1 vs. Placebo</description>
        <time_frame>11 days from Day 1 to Day 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Total Days of Fever</title>
          <description>Total days of fever for MVA-NP+M1 vs. Placebo</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6799</p_value>
            <method>zero-inflated poisson model</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Total Mucus Production</title>
        <description>Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo.&#xD;
Total mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).</description>
        <time_frame>11 days from Day 1 to Day 11</time_frame>
        <population>Total mucus production was only calculated for challenge cohorts 5 to 8 and only if all tissues (cleaned or used) were returned.</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>Average Total Mucus Production</title>
          <description>Total mucus weight of used tissue (regardless of take rate) for MVA-NP+M1 vs. Placebo.&#xD;
Total mucus production was only be calculated in case all tissues were returned (sum of clean and used tissues returned should be 20 tissues for each bag).</description>
          <population>Total mucus production was only calculated for challenge cohorts 5 to 8 and only if all tissues (cleaned or used) were returned.</population>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.09" lower_limit="16.23" upper_limit="45.85"/>
                    <measurement group_id="O2" value="38.21" lower_limit="16.78" upper_limit="59.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5911</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence</title>
        <description>T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay.&#xD;
For each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO).&#xD;
The number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported.&#xD;
The endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.</description>
        <time_frame>3 months (day 0, day 8 and day 28 of the vaccination period and day -1 and day 28 of the challenge period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
          <group group_id="O2">
            <title>Placebo (ITT)</title>
            <description>Intention-to-treat</description>
          </group>
        </group_list>
        <measure>
          <title>T Cell Responses as Defined by ELISpot Assay in Relation to the Primary Endpoint, Symptom Scores and Influenza Incidence</title>
          <description>T Cell Response was assessed for IFN gamma and granzyme B, on the peripheral blood mononuclear cell using a double-colour enzymatic ELISpot assay.&#xD;
For each of them, three stimulation antigens were assessed: nucleoprotein NP, matrix1 M1 and a negative control, dimethyl sulfoxide (DMSO).&#xD;
The number of spot-forming T cell colonies per well (i.e. 200,000 cells) +/- standard deviation for the total response to NP+M1 is reported.&#xD;
The endpoint was recorded as the mean spot-forming units per million peripheral blood mononuclear cells in the peptide-stimulated wells minus the mean DMSO control wells for the sample. T cell responses over time (sampling timepoints) were then assessed in relation to the primary endpoint, symptom scores, and influenza incidence.</description>
          <units>Spot-forming units per million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230" spread="265"/>
                    <measurement group_id="O2" value="167" spread="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8 (from Vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="645" spread="634"/>
                    <measurement group_id="O2" value="170" spread="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 (from Vaccination)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="566" spread="551"/>
                    <measurement group_id="O2" value="163" spread="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 Challenge Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="460" spread="471"/>
                    <measurement group_id="O2" value="159" spread="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28 Challenge Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="561" spread="483"/>
                    <measurement group_id="O2" value="329" spread="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms</title>
        <description>Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries</description>
        <time_frame>7 days following vaccination</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1</title>
            <description>Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)&#xD;
MVA-NP+M1: Trial Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Saline Placebo</title>
            <description>Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%); Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)&#xD;
Saline: Sodium Chloride Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With MVA-NP+M1 Vaccination Related Adverse Events and Symptoms, Measured by Self-reported Symptoms</title>
          <description>Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following vaccination; self-reported symptoms recorded using paper diaries</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE or solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Grade 3 solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Grade 3 solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE of special interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥3 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥3 TE laboratory toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE related to treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE related to treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥3 TEAE related to treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE for which the study was discontinued</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms</title>
        <description>Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring</description>
        <time_frame>17 days following vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVA-NP+M1 (Challenge)</title>
            <description>Safety Analysis Set (challenged participants)</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Challenge)</title>
            <description>Safety Analysis Set (challenged participants)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With H3N2 Challenge Related Adverse Events and Symptoms, Measured by Self-reported Symptoms</title>
          <description>Occurrence of solicited local and systemic reactogenicity signs and symptoms; self-reported symptoms recorded using questionnaires and adverse event monitoring</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE or solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Grade 3 solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Grade 3 solicited symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE of special interest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥3 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥3 TE laboratory toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE related to challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE related to challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade ≥3 TEAE related to challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE for which the study was discontinued</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Severity of Individual Symptoms for MVA-NP+M1 vs. Placebo</title>
        <description>Severity of individual self-reported symptoms for MVA-NP+M1 vs. Placebo</description>
        <time_frame>11 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Symptom Score Time to Start, Time to Peak and Duration</title>
        <description>Time to start; time to peak and duration of total self-reported symptom score, regardless of take rate&#xD;
Influenza Symptom Score Card of FLU010 - Solicited symptoms for generalized, and upper and lower respiratory tract symptoms scored by severity (0: absent, 1: mild, 2: moderate, or 3: severe).</description>
        <time_frame>11 days</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of T Cell Phenotypes With Illness Outcomes</title>
        <description>Correlation of antigen specific T Cell phenotypes with illness outcomes</description>
        <time_frame>3 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Vaccination Effect on Antibody Responses by ELISpot and ICS Assays</title>
        <description>Antibody responses of MVA-NP+M1 vs Placebo following influenza challenge measured by ELISpot and Intracellular Cytokine Staining (ICS)</description>
        <time_frame>3 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Any time during the study from the first administration of any study drug until the last study-related activity (the outpatient visit at 27 days ±3 days following the challenge or 6 months following vaccination ±14 days, whichever is longer)</time_frame>
      <desc>Treatment-emergent adverse events (TEAE) are defined as the Adverse Events starting during or after first administration of any study drug to the end of the study independently of their intensity and if they are related or not to the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>MVA-NP+M1 (Vaccination Phase)</title>
          <description>Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.);&#xD;
MVA-NP+M1: Trial Vaccine</description>
        </group>
        <group group_id="E2">
          <title>Saline Placebo (Vaccination Phase)</title>
          <description>Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%);&#xD;
Saline: Sodium Chloride Placebo</description>
        </group>
        <group group_id="E3">
          <title>MVA-NP+M1 (Challenge Phase)</title>
          <description>Vaccination administered: MVA-NP+M1 (IM injection, 0.5 ml, 1.5 x10^8 pfu.);&#xD;
MVA-NP+M1: Trial Vaccine&#xD;
Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)</description>
        </group>
        <group group_id="E4">
          <title>Saline Placebo (Challenge Phase)</title>
          <description>Vaccination administered: Sodium Chloride (IM injection, 0.5 ml, 0.9%);&#xD;
Saline: Sodium Chloride Placebo&#xD;
Challenge Virus administered: H3N2 (nasal spray, 0.5 ml, 1.0x10^6 TCID50/ml)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="58"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="71"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Swelling of Eyelid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Eye Irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Arthropod Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Ligament Sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin Irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Scar Excision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tom Evans, MD</name_or_title>
      <organization>Vaccitech Ltd.</organization>
      <phone>+44 01865 591 445</phone>
      <email>enquiries@vaccitech.co.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

